Bioequivalence Study of 200 mg Lamotrigine Tablet Under Non-Fasting Conditions
- First Posted Date
- 2009-02-03
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- Teva Pharmaceuticals USA
- Target Recruit Count
- 32
- Registration Number
- NCT00835263
- Locations
- 🇨🇦
Anapharm Inc., Sainte-Foy, Quebec, Canada
Divalproex Sodium Delayed-Release Tablets Under Fasting Conditions
- First Posted Date
- 2009-02-03
- Last Posted Date
- 2009-08-20
- Lead Sponsor
- Teva Pharmaceuticals USA
- Target Recruit Count
- 24
- Registration Number
- NCT00834639
- Locations
- 🇺🇸
PRACS Institute, Ltd., Fargo, North Dakota, United States
Zolpidem Tartrate 10 mg Tablets Under Fasting Conditions
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-02-02
- Last Posted Date
- 2024-08-21
- Lead Sponsor
- Teva Pharmaceuticals USA
- Target Recruit Count
- 38
- Registration Number
- NCT00833521
- Locations
- 🇺🇸
Novum Pharmaceutical Research Services, Pittsburgh, Pennsylvania, United States
Zolpidem Tartrate 10 mg Tablets Under Non-Fasting Conditions
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-02-02
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- Teva Pharmaceuticals USA
- Target Recruit Count
- 24
- Registration Number
- NCT00833937
- Locations
- 🇺🇸
Novum Pharmaceutical Research Services, Pittsburgh, Pennsylvania, United States
🇺🇸Bioassay Laboratory, Inc., Houston, Texas, United States
Terbinafine HCl 250 mg Tablet Formulations Under Non-Fasting Conditions
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-02-02
- Last Posted Date
- 2023-05-30
- Lead Sponsor
- Teva Pharmaceuticals USA
- Target Recruit Count
- 22
- Registration Number
- NCT00833664
- Locations
- 🇺🇸
Novum Pharmaceutical Research Services, Pittsburgh, Pennsylvania, United States
Terbinafine HCl 250 mg Tablet Under Fasting Conditions
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-02-02
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- Teva Pharmaceuticals USA
- Target Recruit Count
- 28
- Registration Number
- NCT00833586
- Locations
- 🇺🇸
Novum Pharmaceutical Research Services, Pittsburgh, Pennsylvania, United States
Risperidone 1 mg Tablet in Healthy Subjects Under Fasting Conditions
- First Posted Date
- 2009-01-27
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- Teva Pharmaceuticals USA
- Target Recruit Count
- 30
- Registration Number
- NCT00830349
- Locations
- 🇨🇦
Anapharm Inc., Sainte-Foy, Quebec, Canada
A Relative Bioavailability Study of 200mg/5 mL Azithromycin Oral Suspension Under Non-Fasting Conditions
- First Posted Date
- 2009-01-27
- Last Posted Date
- 2024-08-20
- Lead Sponsor
- Teva Pharmaceuticals USA
- Target Recruit Count
- 80
- Registration Number
- NCT00830336
- Locations
- 🇺🇸
PRACS Institute Ltd., Fargo, North Dakota, United States
A Relative Bioavailability Study of 200mg/5 mL Azithromycin Oral Suspension Under Fasting Conditions
- First Posted Date
- 2009-01-27
- Last Posted Date
- 2024-08-20
- Lead Sponsor
- Teva Pharmaceuticals USA
- Target Recruit Count
- 80
- Registration Number
- NCT00830206
- Locations
- 🇺🇸
PRACS Institute, Ltd., Fargo, North Dakota, United States
Dexmethylphenidate Hydrochloride Tablets Under Fasting Conditions
- First Posted Date
- 2009-01-27
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- Teva Pharmaceuticals USA
- Target Recruit Count
- 24
- Registration Number
- NCT00829712
- Locations
- 🇺🇸
Gateway Medical Research, Inc., Saint Charles, Missouri, United States
© Copyright 2024. All Rights Reserved by MedPath